Summary
Nolla Health says its Nolla Derm app has begun a Utah pilot that can issue initial acne-treatment prescriptions to residents aged 18 and older. The staged program starts with physician approval of every AI-generated prescription.
Nolla Health says its Nolla Derm app has started a Utah pilot in which an AI system can issue initial prescriptions for acne treatment, rather than only renew existing prescriptions. The company says it developed the pilot with the Utah Office of Artificial Intelligence Policy and secured authorization for it, describing the programme as a first in the United States.
The pilot is open to Utah residents aged 18 and older. Nolla says enrollment is offered at a discounted $4.99 per month. After verifying their identity and giving informed consent, patients complete an intake questionnaire and a five-angle face scan. The company says the process takes about 10–15 minutes and produces a treatment plan and, when appropriate, an initial prescription.
Nolla frames the service as a way to address barriers to dermatology care. It reports that Utah’s average wait for a dermatology appointment is 61 days and that 11 counties have no dermatologist. Those access figures are part of the company’s case for offering an app-based service; the announcement focuses on the pilot’s design and launch.
Physician oversight changes by pilot stage
Under the announced plan, the first 100 patients are in stage one. Two licensed physicians independently review and approve every AI-generated prescription before it reaches a patient. This stage lasts at least four weeks.
In stage two, covering up to 500 patients, the app can issue prescriptions directly. A physician then reviews every case after the fact at least weekly. The stage lasts at least eight weeks. In stage three, physicians review a sample of at least 10% of prescriptions each month, as well as every case involving an escalation or side effect.
Moving between stages requires meeting safety targets, including 95% agreement with physicians and zero serious adverse events, as well as written approval from the state. These steps make the pilot’s oversight a planned part of the service, rather than an optional consultation after an AI recommendation.
A constrained system for a defined treatment scope
Nolla describes the system as selecting among pre-approved topical treatment plans using structured clinical information and an AI assessment of the face scan. It says the prescription process has no free-text interface. Severe acne, pregnancy and other conditions outside the pilot are directed to a licensed physician or in-person care instead of receiving an AI prescription.
Patients can message a licensed physician through the app at any time without an extra charge, and Nolla says those messages are answered by physicians, not AI. The company also says daily skin scans track progress and that treatment plans are reviewed after every 28 scans.
Nolla reports that licensed clinicians agree with its treatment recommendations in 96% of real-world cases, with differences described as minor adjustments. The announcement does not give a sample size or evaluation method for that figure, so it is best understood as a company-reported clinician-agreement measure, not a reported acne-treatment outcome. The launch describes a staged service pilot, with its initial prescriptions subject to physician approval and later stages dependent on safety targets and state approval.